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Interleukin-10 (IL-10) is an immunoregulatory cytokine that plays a pivotal role in
modulating inflammation. IL-10 has inhibitory effects on proinflammatory cytokine
production and function in vitro and in vivo; as such, IL-10 is viewed as a potential
treatment for various inflammatory diseases. However, a significant drawback of using
IL-10 in clinical application is the fact that the biologically active form of IL-10 is
an unstable homodimer, which has a short half-life and is easily degraded in vivo.
Consequently, IL-10 therapy using recombinant native IL-10 has had only limited success
in the treatment of human disease. To improve the therapeutic potential of IL-10, we have
generated a novel form of IL-10, which consists of two IL-10 monomer subunits linked
in a head to tail fashion by a flexible linker. We show that the linker length per se did
not affect the expression and biological activity of the stable IL-10 molecule, which was
more active than natural IL-10, both in vitro and in vivo. We confirmed that the new
form of IL-10 had a much-improved temperature- and pH-dependent biological stability
compared to natural IL-10. The IL-10 dimer protein binds to the IL-10 receptor similarly
to the natural IL-10 protein, as shown by antibody blocking and through the genetic
modifications of one monomer in the IL-10 dimer specifically at the IL-10 receptor binding
site. Finally, we showed that stable IL-10 is more effective at suppressing LPS-induced-
inflammation in vivo compared to the natural IL-10. In conclusion, we have developed
a new stable dimer version of the IL-10 protein with improved stability and efficacy to
suppress inflammation. We propose that this novel stable IL-10 dimer could serve as the
basis for the development of targeted anti-inflammatory drugs.
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INTRODUCTION
IL-10 is a pleiotropic cytokine that is produced by different cell types, including myeloid cells
(dendritic cells, macrophages, eosinophils, neutrophils, and mast cells) and lymphoid cells (NK,
B cells, and T cells) with broad anti-inflammatory activity. Macrophages and myeloid dendritic
cells express IL-10 upon activation of MyD88 and TRIF-dependent TLR pathways such as TLR3
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and TLR4, by stimulation with dsDNA and LPS, respectively
(1).Moreover, tolerogenic dendritic cells (CD11clowCD45RBhigh)
produce large amounts of IL-10 in response to LPS, which
induces T regulatory cell development (2, 3). Natural regulatory
cells (nTreg) produce IL-10 in the response to IL-2, which is vital
for immune homeostasis (4).
Structurally, IL-10 belongs to the class II cytokine family,
which involves IL-19, IL-20, IL-22, IL-24 (Mda-7), IL-26, and
interferons (IFN-α, -β, and -γ) (5). The IL-10 is a member of
helical cytokines as an IL-10 monomer consists of six α-helices
(A-F) (6). Biologically active IL-10 is a non-covalent homodimer,
which is described as a three-dimensional (3D) domain swapping
protein with a molecular mass of 37 kDa (18.5 kDa for each one)
(7–9). The IL-10 receptor (IL-10R) is a member of the class II
cytokine receptor family and consists of two subunits, IL-10R1
and IL-10R2 (10, 11). IL-10 binds to IL-10R with high affinity;
however, it can be species-specific. For example, mouse IL-10 was
able to block the binding of human IL-10 to mouse cells but not
human cells (12). Analysis of the protein crystal formed of IL-10
bound to soluble IL-10R1 revealed that the 3D domain-swapped
homodimer IL-10, which consists of helices E and F from one
chain inserted into the hydrophobic cleft formed by into helices
A–D of the other chain, is essential for receptor-binding (13). IL-
10 binding to the IL-10R complex activates a Janus kinase- Signal
Transducers and Activation Transcription system (JAK/STAT)
signaling pathway. IL-10/IL-10R promotes phosphorylation and
activation of the transcription factor STAT3, which is required for
the IL-10 immunoregulatory effect (14).
The anti-inflammatory activity of IL-10 is in part due to
the inhibition of the synthesis of pro-inflammatory cytokines
such as tumor necrosis factor (TNF) (15). Furthermore, IL-
10 downregulates MHC class II expression and helps to
promote wound healing (5, 16). The IL-10 showed to have an
immunoregulatory effect during an infection with Toxoplasma
gondii (17), Mycobacterium spp. (18), Herpes simplex virus (19),
and malaria (20) by ameliorating the exaggerated T helper 1
and CD8+ T cells response including. A defect of IL-10 or the
IL-10 receptor has been linked to excessive immune reactions
and a disposition to chronic inflammatory disease, such as the
early onset of inflammatory bowel disease (21–23). Also, changes
of the gut microflora could lead to a change in the regulation
of the gut-associated immune system, resulting in chronic gut
inflammation, which in part could be the result of dysregulated
IL-10 expression (21, 24).
Here we report the generation of a new form of IL-10 more
suitable for therapeutic intervention, as the natural IL-10 has
only a short half-life in vivo. The stability of the non-covalent
IL-10 dimer strongly depends on physical parameters such as
temperature and pH. The IL-10 dimer dissociates to amonomeric
form at low protein concentrations or at acidic pHs, as typically
found in inflamed tissue. Acidic pH has been found, for instance,
in fracture-related hematomas (ranging as low as pH 4.7), in
cardiac ischemia (pH 5.7) (25). Examinations of inflamed skin
showed pH values of 5.8–7.2 (25–27). It has been demonstrated
that ∼10 and ∼50% of human IL-10 was dissociated (i.e.,
decayed) when heated to 37 and 55◦C, respectively, for 1 h (9).
Moreover, to date, the free IL-10 monomer has not been found in
the solution. The IL-10 monomer could not exist in solution due
to the presence of significant hydrophobic residues, which are
shielded by interaction involved in the dimer form (6). Therefore,
we reasoned that the generation of a stabilized dimer form of
IL-10 might be a promising approach to overcome the inherent
IL-10 instability and thereby improve its therapeutic potential.
One way to improve the stability of the IL-10 structure has
been proposed by generating a stable IL-10 dimer using an
internal flexible linker (28). Expressing the dimer as a single
continuous fusion protein in which the monomers are connected
by a flexible linkers (Gly-Ser) may offer a stability advantage
and improve biological activity (29). Moreover, Gly-Ser linkers
in recombinant proteins could play a general role in overall
stability and solubility. A previous study has shown that using
a Gly-rich linker to tether the dimeric forms of HIV-1 proteases
(HIV-PR) results in a more stable form compared to the natural
HIV-PR at pH 7.0 (30). Moreover, Foss et al. showed that using
flexible linkers (Gly-rich linker) in transthyretin, the carrier
of the thyroid hormone, is more stable than the natural after
urea treatment (31). We now generated a functional IL-10 by
linking two monomers using a flexible linker. We examined and
compared the biological activity of the stable IL-10 dimer against
the natural or non-covalently linked IL-10, both in vitro and in
vivo. Here, we demonstrate that novel recombinant IL-10 dimer
has improved stability and higher biological activity; therefore,
it has the potential to be a building block for future IL-10 based
immunotherapy treatment regimes.
METHODS
Plasmid Design and IL-10 Construct
The eukaryotic expression vector pCEP V19 was used to
express the cDNA of natural mouse IL-10 (Nm) and stable
mouse IL-10 (STm). The C-terminus of pCEP V19 includes
Factor XA (FXA), human serum albumin (HSA), thrombin.
oriP: replication origin of Epstein-Barr virus, EBNA-1: Epstein-
Barr virus nuclear antigen-1, ampicillin: ampicillin resistance
gene (β-lactamase), pUC ori: the bacterial origin of replication,
puromycin: puromycin resistance gene, CMV: Promoter of
cytomegalovirus, BM40: a signal sequence of protein BM40,
8 His tag: 8 histidine residues, thrombin: thrombin, NheI,
Bsu36I, BamHI: restriction sites, mouse IL-10 cDNA, SV40 pA:
polyadenylation signal of SV40 Virus. The expression vector
was generated and provided to us by Manuel Koch (Institute
of Biochemistry II, University of Cologne). The nine amino
acids (-G3SG4S-) and 13 amino acid linker(-G3SG4-SG4-) were
generated by inserting the synthetic insert into the second
monomer of mouse IL-10. The stable IL-10 cDNA was digested
with the BamHI enzyme before ligating the synthetic inserts
containing a nine and 13 amino acid linker with 5′ BamHI
restriction site and 3′ BglII restriction sites. The confirmation
of the correct insert orientation was carried out using NheI
and BamHI restriction digestion. The stable human IL-10
(STh), and mutant cDNAs of mouse IL-10 were synthesized
(GeneArt Gene Synthesis: Thermofisher). Oligonucleotides were
cloned into pMA-RQ, Col E1 origin: the bacterial origin of
replication, ampicillin: ampicillin resistance gene (β-lactamase)
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(Thermofisher), then subcloned into the eukaryotic expression
vector pCEP V19.
Transfection of HEK293EBNA, IL-10
Expression, and Purification
HEK293EBNA (HEK) mammalian cell line was generated from
human embryonic kidney cells. The cell line was maintained
in Dulbecco’s modified Eagle’s medium (DMEM) with 4.5
g/L glucose, 10% fetal bovine serum (FBS) (Life Technologies
Ltd), 1% L-Glutamine, and 1% Penicillin-Streptomycin (Pen-
Strep) (Sigma). HEK cells carry the Epstein-Barr Virus Nuclear
Antigen-1 (EBNA-1) gene and allow for improved protein
production since plasmids replicate competently in positive
cells. HEK cells were transfected using Lipofectamine 3000
(Invitrogen). HEK cells were first seeded at 1 × 106 cells/well
in a 6-well plate. Upon reaching a confluence of ∼80–90%, 5
µg of the plasmid DNA was mixed with different volumes of
lipofectamine 3000 (3.5 and 7.5 µl) in 125 µl of Opti-MEMTM
(Thermofisher), and the mixture was incubated for 15min at
room temperature. Afterward, the lipo-DNA mixture was added
dropwise onto the cells. After 24 h, the cells were washed once
with PBS, and selection media containing puromycin (Gibco)
was added (DMEM, 10% FBS, 1% Pen-Strep, 1% of L-Glutamine,
(2µg/mL) and incubated for 3 days. The cells were then washed
with PBS before adding fresh medium minus puromycin. The
supernatant was harvested and stored at −20◦C until further
use. The transfected cell supernatant was loaded at 4◦C onto
a HisTrap HP column (GE Healthcare). The column was then
washed with 10 CV of binding buffer, followed by stepwise
elution of the protein with increasing imidazole concentration
(50, 100, 250, and 500mM) in binding buffer. Protein content and
purity of each fraction were visualized by Coomassie staining.
Positive fractions were pooled and dialyzed at 4◦C against PBS.
Animal Models
Cells derived from mice that were used in the in vitro
experiments were housed at the University of Manchester
Biological Services Facility (BSF) under specific-pathogen-
free conditions. They had easy access to food and water
on a 12/12-h light cycle. All breeding mice were routinely
screened (3 monthly or annually where applicable) according
to BSF recommendations. The mouse strains (hTNF.LucBAC
and C57BL/6) were bred in this study under a Home Office
project license (70/7800) (P8829D3B4) in agreement with the
Animal (Scientific Procedures) Act 1986. The C57BL/6 mice
were ordered from Charles River (Charles River Laboratories,
Inc., Harlow, UK). The in vivo experiments were performed at
the University of Cologne, Germany, under animal experimental
license 24-9168.11-1/2009-22.
Purification of Bone Marrow-Derived
Macrophages
Mouse bone marrow-derived macrophages cells (BMDMs) were
isolated, as described previously (32). Briefly, bone marrow-cells
were dissected from femurs and tibiae and plated into a complete
media (RPMI 1640 medium (Sigma) supplemented with 10% v/v
FBS (Life Technologies Ltd), 100 IU/mL penicillin 100µg/mL
streptomycin (Sigma), 50 ng/mL mouse colony-stimulating
factor (MCSF) (Promega), and 50µM β-mercaptoethanol)
(Sigma) at 5 × 106 cells per 90mm bacterial petri dish (Sterilin,
UK) for 4 days. On day 4, 10mL of complete media was added
and incubated for 3 days. Adherent cells were then harvested
with 5mL of PBS supplemented with 5% v/v FBS and 2.5mM
EDTA. For splenocyte isolation, the spleen was homogenized and
filtered through nylon mesh filters (70µM; Becton Dickinson,
UK) to generate a single-cell suspension. RBCs were lysed with
ammonium chloride potassium (ACK) lysis buffer before the cell
pellet was resuspended in DMEM medium supplemented with
10% v/v/FBS, 1% w/v/Penicillin/Streptomycin, 1mM glutamine
and 50 µM β-mercaptoethanol.
Cell-Based Luciferase Reporter Assay
The cell-based luciferase reporter assay has been previously
described (32). BMDMs were plated in 96 well plates (OptiPlate-
96, White Opaque 96-well Microplate; Perkin Elmer, UK) at
1 × 105/well in 0.1mL medium containing 1mM luciferin
(Promega) and left to rest overnight. Cells were stimulated
with LPS (Salmonella enterica serovar Minnesota R595; Alexis
Biochemicals, UK) (10 ng/mL) alone or in the presence of
commercial mouse IL-10 mouse (Protech), natural or stable IL-
10 proteins. The anti-IL-10R antibody (clone: 1B1.3a) (Biolegend
UK Ltd) was used to validate that the alteration in the luciferase
response observed was dependent on the IL-10 receptor’s
engagement with IL-10. Unstimulated cells were used as a
negative control. The luciferase activity was measured over time
in a CO2 Lumistar Omega luminometer (BMG Labtech, UK).
Temperature- and pH-Dependent Stability
Study
Stability experiments were performed as previously described (9),
with the biological activity of IL-10 being monitored by luciferase
assay. Briefly, 0.1µg/mL of IL-10 sample was incubated at 55◦C
in time-course (to 30min). The pre-heated IL-10 sample was
added together with LPS on hTNF.LucBAC BMDMs and the
luciferase activity was monitored over time. The pH-effect on
the biological stability was determined by first pre-incubating a
0.1µg/mL sample in different pH buffers (sodium citrate pH 2.5,
sodium phosphate pH 5.5–6.5 and TRIS-base pH 8.0–10.0) for
24 h at 4◦C followed by buffer exchange with PBS using a spin
Desalting column (Thermofisher). Protein was diluted to a final
concentration in each experiment of 10 ng/mL before testing for
biological activity.
Enzyme-Linked Immunosorbent Assay
(ELISA) for IL-10
The recombinant fusion mouse and human IL-10 proteins were
detected after purification using Ready Set Go ELISA kits (Cat
mIL-10 50-112 eBioscience, UK, Cat hIL-10 88-7106) according
to the manufacturer instructions. Briefly, 96-well flat-bottom
high-affinity ELISA plates were coated overnight at 4◦C with
the capture antibody. Plates were washed three times with
washing buffer (0.05% Tween 20 PBS) before the addition of
blocking buffer to each well with 1X ELISA Diluent (supplied)
for 1 h. Standards were prepared and added in 2-fold serial
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dilutions (4,000–31.25 pg/mL) after washing the plate three
times as above. The recombinant protein was diluted 100-
fold before serial dilution (1/2) were incubated for 2 h at RT.
The detection antibody was added and incubated for 1 h after
washing three times with washing buffer as above. Plates were
further rewashed three times before incubation with streptavidin-
horseradish peroxidase (HRP) for 30min at RT. Plates were then
washed five times with substrate solution, Tetramethylbenzidine
(TMB). After incubation for another 15–30min at RT in the
dark, stop solution (2N H2SO4) was added (25 µl) to each
well. Optical density was measured using Versa-Max ELISA
Microplate Reader with 450 filter.
Western Blot
Purified IL-10 was detected by western blot using the anti-mouse
IL-10 (JES5-2A5) (eBiosciences). For Splenocytes (5× 106) were
either left unstimulated or were stimulated with either Nm or
STm for 24 h After 24 h cells were washed three times with cold
PBS and lysed in 0.5mL of RIPA Buffer (Sigma) containing 5
ul of Protease Inhibitor Cocktail (Sigma) and incubated on ice
for 5min. Samples were then centrifuged at 5,000 × g for 5min,
and the supernatants stored at−20◦C. A nanodrop machine was
used to determine the concentration of the protein (absorbance
at 280 nm) for each sample. The total protein concentration was
adjusted in all samples with the addition of a RIPA lysis buffer.
Protein samples were loaded onto 4–12% BIS-Tris Gels
(Invitrogen) using running buffer MED SDS (Invitrogen). 24 µl
of sample and 6 µl of SDS Sample Buffer (4X) (Thermofisher)
were mixed and heated at 80◦C for 5min. 10µl of electrophoresis
marker (Sigma) was used to determine the molecular size. The
gel was run at 100V until the tracking dye reached the bottom
of the gel. The gel was removed from the gel cassettes and
placed in the nitrocellulose membrane (Bio-Rad) and blotted
using the Trans-Blot Turbo Transfer System (Bio-Rad). The blot
was then incubated with blocking solution (5% w/v milk in TBS-
Tween) for 90min at room temperature; before incubation with
a primary antibody: anti-rat IL-10 (JES5-2A5) (eBiosciences),
anti-mouse total STAT3 (Cell signaling), and anti-rabbit p-
STAT3(Cell signaling) in 1:1000 in 5% w/v milk in TBS-Tween
overnight at 4◦C. After that, the blots were washed four times
with TBS-Tween for 20min; before incubated with the secondary
antibody (horseradish-peroxidase (HRP)-conjugated goat anti-
mouse or anti-rabbit (Cell signaling) at 1:2000 in 5% w/v milk
in TBS-Tween for 60min. The signals were developed using a
Western Blot Chemiluminescent Substrate (ECLwestern blotting
substrate (Cell signaling).
In vivo Experiments
Treatment of LPS-induced inflammation of the skin with IL-10:
On three consecutive days, 10 µg each of LPS in a volume of
50 µl, with or without varying amounts of Nm or STm, were
injected into the flank at the same site. On the 5th day, the
tissue surrounding the injection site became removed en bloc
and hematoxylin and eosin (H & E) stained. The tissue in 4%
formalin was cut to 5 microns thickness using a microtome.
After drying the sections onto slides, the deparaffinization and
rehydration stages were carried out. The preparations were
subsequently stained with Mayer’s hemalum solution (Sigma)
and eosin (Sigma), dehydrated again, and covered with entellan
(Merck). When viewed in the light microsphere, the basic
cytoplasm, elastin, and collagen appeared red-orange, the nuclei
dark blue, and erythrocytes yellow-orange.
Treatment of Endotoxin Shock by IL-10: 100 µl PBS
containing 25 µg LPS (serotype 055: B5) was injected retro-
orbitally (i.v) in C57BL/6 mice (8–12 weeks) to indicate the
optimum time for TNF synthesis after LPS treatment. To test the
efficacy of IL-10 in TNF suppression, C57BL/6 mice were pre-
treated with different amounts of either PBS, Nm or STm (2 µg
each) for 30min before injecting LPS (10 µg) At the indicated
time points (1.5, 3, or 6 h), blood was taken retro-orbitally,
and ELISA used to determine the TNF serum concentration.
IL-10−/− mice were given 10 µg LPS together with increasing
concentrations of Nm or STm being injected intravenously. After
3 h, blood was withdrawn, and the IL 6 serum concentration
determined by ELISA.
Statistical Analysis
Results were represented as the mean ± standard error of the
mean (SEM). Following assessment for normality and equality
of variances, statistical inferences on data were performed using
one-way, or two-way analysis of variance (ANOVA) followed by
unpaired comparisons of treatment means using Dunnett’s post-
hoc test (LPS-treated or vs. LPS+IL-10) used in the luciferase
inhibition assay and (untreated or vs. treated) used in the stability
study. Differences were considered statistically significant when
p < 0.05. Luciferase activity represented as area under the
curve (AUC) Statistical analyses were performed using GraphPad
Prism-7 Software Statistical Package, La Jolla CA; the USA.
RESULTS
Generation, Expression, and Purification of
a Stable IL-10 Protein Using a Mammalian
Expression System
The crystal structure of the IL-10 dimer shows that the C-
terminus of one monomer is in close proximity to the N
terminus of the second monomer due to 3D domain swapping
with the antiparallel association. This suggested that a stabilized
dimer could be generated by linking these two termini. A
new recombinant stable IL-10 was generated by cloning two
copies of the same IL-10 cDNA in tandem as a continuous
polypeptide in the same orientation separated by 7 amino acids
linkers (-G3SG3-) (Figure 1A). Because glycine-serine linkers
do not form α-helices and have no reactive side chains (34),
they are often used for a flexible and neutral connection of
protein domains. Importantly, molecular dynamics simulation
(Figure 1B) suggested that the linker would not interfere with the
secondary structure of the monomers or IL-10 receptor binding
site. In this report, we name the natural IL-10 (non-covalently
linked) from mouse as Nm and human as Nh; besides, we name
the stable IL-10 dimer from themouse as STm and human as STh.
Both STm and Nm were generated from HEK cells with
a His-tagged pCEP V19 expression vector. Recombinant Nm
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FIGURE 1 | Expression and ELISA measurement of natural and stable mouse IL-10. (A) The cDNA construct of both natural mouse IL-10 (Nm) and stable mouse
IL-10 (STm). The cartoon illustration of the expected protein folding of both Nm and STm versions. (B) The ribbon plot of the natural IL-10 homo-dimer with N and C
terminus obtained from the previous study (13) and the molecular dynamics simulation of stable IL-10. The basis for this simulation is the crystal structure of the
hIL-10 dimer (33) (PDB-ID: 2ILK). After about 2 ns of simulated time, the state of the system shown here was found. The peptide linker (-G3SG3-) is colored red. The
molecular simulation of stable IL-10 was carried out by Jan-Philip Gehrcke (Biotechnology Center Dresden). (C) Both Nm and STm were stained with Coomassie Blue
under reducing condition in SDS-page and (D) detected by IL-10 antibody in Western Blot. (E) Nm (black line) and STm proteins (blue line) were detected ELISA (1/2
dilutions). All data are representative of triplicate wells, and the bars represent standard error of the mean.
and STm proteins from parental vector-transfected cells were
subjected to purification by an N-terminal His-tag purification
column and analysis by SDS-PAGE andWestern blotting. Under
reducing conditions, the Nm migrated as a monomeric band in
the region of 23 kDa, while the STm as a stable dimer migrated as
a dimer band of ∼41 kDa in SDS-PAGE (Figure 1C). This result
corresponds to the calculated molecular weights of 18.7 for IL-10
monomers and 37.3 kDa for IL-10 dimers, respectively (35). Both
proteins were also detected using a specific IL-10 antibody (clone:
JES5-2A5) in the western blot with different migration profiles
due to the monomeric and dimeric forms (Figure 1D). Finally,
both STm and Nm were detected by IL-10-ELISA to determine
the recombinant IL-10 protein concentrations (Figure 1E) with
a commercially sourced IL-10 protein (CmIL-10) (PeproTech)
being used as an internal standard.
The Biological Activity of Stabilized Mouse
IL-10 Dimer in vitro
Different approaches were used to measure the biological
activities of the various versions of the IL-10 proteins we
generated. First, we determined IL-10 activity by detection
of STAT3 phosphorylation in IL-10 treated lymphocytes. To
demonstrate proof of concept, spleen cells from wild-type, IL-
10−/−, and IL-10R1−/− mice were prepared and stimulated with
the purified IL-10 proteins (5 ng/mL). Phosphorylated STAT3 (p-
STAT3) (75 kDa) was detected by western blot analysis of cell
lysates. Both STm and Nm induced p-STAT3 in murine wild-
type and IL-10−/− but not in IL-10R1−/− receptor-deficient cells
(Figure 2A), demonstrating that the STm IL-10 uses the IL-10R
for signaling.
We compared regulatory activities of STm, Nm, and
commercial mouse IL-10 (CmIL-10) using BMDMs isolated from
the hTNF.LucBAC reporter mouse reports the activation of the
human TNF gene promoter, as previously described (32). STm,
Nm, and CmIL-10 (all at 10 ng/mL) significantly suppressed the
LPS-induced luciferase production by about 60% (p < 0.001
ANOVA) (Figure 2B) Subsequently, we titrated STm and Nm
IL-10 and determined half-maximal suppression of luciferase
induction (ED50) values of 0.04 and 0.17 ng/mL for STm and
Nm, respectively (Figure 2C). For validation of this result, we
isolated the supernatant of LPS- and IL-10-treated BMDMs
after 24 h and measured soluble mouse TNF by ELISA. This
alternative readout yielded ED50 values in the same range as
obtained by quantification by the bioluminescence reporter
system (Figure 2D). Thus, STm was 4- to 8-fold more active
than natural IL-10. Likewise, Western blot analysis of STAT3
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FIGURE 2 | Stable mouse IL-10 (STm) is biologically active in vitro. (A) Specific induction of STAT3 phosphorylation by STm (5 ng/mL) was verified by the use of
spleen cells from different mouse lines: Wild type C57BL/6 (WT), IL-10 knockout (IL-10−/−) and IL-10 receptor knockout (IL-10R1−/−). (B) Luciferase activity was
(Continued)
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FIGURE 2 | monitored as the area under the curve (AUC) from BMDMs reporter mouse; cells were either unstimulated or stimulated with LPS (10 ng/mL) in the
presence or absence of IL-10 from HEK293 EBNA supernatants. A commercial mouse IL-10 (CmIL-10) was used as a positive control, and un-transfected cells
supernatants (Medium) served as a negative control. Significant difference considered by comparing to LPS stimulated cells as follows: not significant (ns),
***p < 0.001; ANOVA. (C) The dose-response effect of IL-10 on LPS-treated BMDMs of the transgenic mouse: the ED50 of Nm (black line) and STm (blue line) was
calculated as 0.17 and 0.04 ng/mL, respectively. The maximum luciferase induction was determined by treating the BMDMs of the transgenic mouse with LPS alone
at 10 ng/mL as it showed a black dot line. (D) Soluble mouse TNF was measured from the medium 24h from BMDMs of the transgenic mouse either after LPS
stimulation alone or after co-treating with either Nm (black line) or STm (blue line) in a dose-dependent fashion. (E) Splenocyte lysates of the C57BL/6 mouse were
either unstimulated (∅) or stimulated with IL-10 (Natural type or Stable) in a dose-dependent manner. (F) Inhibition of Nm and STm induced STAT3 phosphorylation by
a blocking IL-10 antibody (clone JES5-2A5). IL 10 (2.5 ng) was mixed with the indicated amounts of antibody in one volume of 25 µl of medium and preincubated on
ice for 30min before adding this batch to 475 µl of spleen cell suspension. (G) The Luciferase activity represented as AUC from LPS-induce cells from transgenic
mouse were either unstimulated or treated with 0.2µg/mL of the antiIL-10 receptor (antiIL-10Ra) antibody (clone 1B1.3a) for 30min at 37◦C before treatment with
LPS (10 ng/mL) or LPS (10 ng/mL), Nm (10 ng/mL), or STm (10 ng/mL). Furthermore, a significant difference is also calculated to compered Nm with STm after
antiIL-10Ra treatment; ANOVA. (H) The dose-response stable IL-10 on LPS-treated BMDMs of transgenic mouse: the ED50 of Nm (black line) is 1.5 ng/mL and the
ED50 of STm proteins: STm7 (green) STm9 (blue line) and STm13 (red line) is calculated as 0.45 ng/mL and 0.40 and 0.38 ng/mL respectively. All data are
representative of three independent experiments, with triplicate cultures per experiment (N = 3, n = 3), and bars represent standard error of the mean.
phosphorylation induced by titrating amounts of IL-10 showed
about 100-fold higher activity of STm compared to natural mouse
IL-10 (Figure 2E). As a further test to quantify the biological
activity of STm, we determined concentrations of anti-IL-10mAb
required to inhibit STm-induced STAT3 phosphorylation. While
the activity of Nm was almost entirely blocked by pre-incubation
with 0.05mg/ml anti-IL-10 antibody, this antibody concentration
did not affect STm activity (Figure 2F).
We believe that the suppression of luciferase is dependent
on the IL-10R engagement with IL-10. Therefore, we tested the
capability of the IL-10R antibody to block the effect of IL-10
on LPS-BMDMs of h.TNF.LucBAC. Our data showed that the
presence of anti-IL-10R1 blocking antibodies completely blocked
the biological activity of STm. Our data demonstrate that there
is a non-significant change in the luciferase induction of a pre-
treated BMDMs with 0.2µg/mL anti-IL-10 receptors antibody
(antiIL-10Ra) compared to the BMDMs treated with LPS only
(10 ng/mL) (Figure 2G).
In order to address whether the length of the flexible
linker, which may affect solubility, stability, and function of
the fusion protein, we generated dimeric IL-10 molecules with
different linker lengths -G3SG3- (STm7), -G3SG4S- (STm9), and
-G3SG4-SG4- (STm13) as described above. Linker length did
not impact on the bioactivity of the stable IL-10 as determined
by suppression of LPS-induced TNF reporter expression
(Figure 2H). Collectively, stable mouse IL-10 shows significantly
more potent bioactivity compared to natural mouse IL-10.
Temperature- and pH-Dependent Stability
of Stable Mouse IL-10 Protein
The human IL-10 homodimer was shown to rapidly dissociate
into inactive monomers at lower pH and higher temperature
(9). We compared the effect of temperature and pH on the
biological activity of STm and Nm. A 30min incubation at 37◦C
did not affect the capacity of Nm or STm to suppress LPS-
induced luciferase expression (Figure 3A). Nm lost bioactivity
already upon 5min exposure to 55◦C, whereas the treatment
did not affect STm (Figure 3B, Figure S1A). ED50 of commercial
IL-10 and Nm were significantly reduced by exposure to 55◦C
for 10min while STm was not affected by this treatment
(Figures 3C–E). Moreover, we investigate the impact of acidic
and basic pH on the biological activity of IL-10 protein. Biological
activity of both Nm and STm decreased in acidic and alkaline
pH compared to neutral pH (pH 7). However, at an acidic pH of
5, STm was significantly more active over a wide concentration
range (Figure 3F). We also addressed the effects of freezing
and frozen storage on IL-10 bioactivity. Our data indicate that
the ED50 of STm IL-10 was 0.041 ng/mL, and ED50 Nm was
0.15 ng/mL after storage at −80◦C for 6 months (Figure 3G). In
summary, we show that stable mouse IL-10 is more resistant to
heat and low pH than natural mouse IL-10.
The Effect of the Site-Specific Mutation on
Stable Mouse IL-10 Biology
We predict that the STm bound to IL-10R like Nm (i.e.,
natural IL-10). To investigate this, we mutated the IL-10R
binding site in the STm dimer. The location of the IL-10R
binding site was obtained from the previous study on IL-10/IL-
10R interaction (13). For this purpose, we introduced four-
point mutations (L23G, R27G, K34G, and Q38G) at the helix
A of the second monomer of the STm dimer (Figure 4A).
This mutated form of IL-10 named IL-10M2Mu. The IL-10
ELISA detected the IL-10M2Mu as validation of the presence
of the recombinant protein in culture supernatants of HEK
cells (Figure 4B). The luciferase assay, represented as AUC,
showed that IL-10M2Mu (10 ng/mL) inhibited the luciferase
activity by ∼15% (p < 0.5, ANOVA). However, 50 ng/mL
of IL-10M2Mu inhibited luciferase activity by ∼40% as the
Nm and STm (p = 0.001, ANOVA) (Figure 4C). This data
shows that maximal suppression could be achieved with 5-fold
of IL-10M2Mu compared to STm and Nm. This experiment
may represent the significance of dimerization in STm to
retain the maximum activity by binding to the IL-10R as the
natural IL-10.
In previous investigations, we demonstrated that several
alanine substitutions in the IL-10RRCHR (i.e., natural IL-10)
region have an impact on the structural integrity (α-helical
structure) of IL-10 (Figure 5A), with substitution of RRCHR
to ARCHA causing the most significant loss of structure (36).
Importantly, we found a correlation between changing the degree
of α-helical structure with the reduction in the biological activity
of Nm, as presented in ED50 and confirmed by the p-STAT3 assay
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FIGURE 3 | Biological stability of mouse IL-10 variants upon treatment at different temperatures and pH in vitro. (A) Area Under the Curve (AUC) of luciferase
induction was measured after incubating 100 ng/mL Nm (black line) and STm (blue line) at 37◦C in the time course. (B) Both Nm (black line) and STm (blue line) were
treated at 55◦C in time course before luciferase activity was measured as the area under the curve (AUC) after LPS-stimulated BMDMs of reporter mouse. (C–E)
LPS-induced luciferase inhibition was measured after co-stimulated with either heat-treated at 55◦C for 10min (10min) or untreated (0min) of the commercial mouse
IL-10 (CmIL-10), Nm and STm. CmIL-10 was used as a control in this experiment. The ED50 was calculated as follow: (C) CmIL-10 heat-treated for (2.24 ng/mL) or
(Continued)
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FIGURE 3 | untreated (0.137); (D) Nm heat-treated for (3.23 ng/mL) or untreated (0.8 ng/mL); (E) STm heat-treated for (0.09 ng/mL) or untreated (0.08 ng/mL). (F)
Both Nm and STm at 100 ng/mL were pre-incubated with different pH buffers at 4◦C for 24 h flowed by buffer exchange columns. BMDMs of the transgenic mouse
then stimulated with LPS (10 ng/mL), and pH treated IL-10 (Nm and STm) at 10 ng/mL. The percentage of luciferase activities is relative to LPS treatment. The
significant difference compared between pH treatments with neutral pH (pH7) of Nm and STm on LPS-stimulated cells ***p < 0.001, **p < 0.005, *p < 0.05; ANOVA.
(G) To test the effect of the storage of IL-10 protein in −80◦C for 6 months, the ED50 was calculated and compared between Nm (black line) and STm (blue line). All
data are representative of three independent experiments, with triplicate cultures per experiment (N = 3, n = 3), and bars represent standard error of the mean.
FIGURE 4 | Mutations introduced into one monomer of stable mouse IL-10 at the IL-10R binding site (IL-10M2Mu). (A) The cDNA construct of both un-mutant IL-10
and IL-10M2Mu was cloned into the expression vector (pCEP V19) and the cartoon illustration of IL-10M2Mu with the location of the 4-points mutations at the IL-10
receptor-binding site on the helix A of IL-10 protein. (B) Purified IL-10M2Mu detected by ELISA (1/2 dilutions) to evaluate the expression level. (C) Assessment of
luciferase suppression after LPS (10 ng/mL) treatment and either co-treated with Nm (10 ng/mL), STm (10 ng/mL), or IL-10M2Mu at (10 and 50 ng/mL). The significant
difference is calculated concerning LPS stimulated cells only and symbolized as ***p < 0.001, ns (non-significant). All data are representative of three independent
experiments, with triplicate cultures per experiment (N = 3, n = 3), and bars represent standard error of the mean.
(Figures 5B,C). Based on this data, to further investigate the
biological properties and the IL-10R binding of the engineered
STm, we assessed the corresponding impact of these substitutions
on the biological activity of STm. Our data showed that these
mutations affected the biological activity of STm to a different
extent compared to Nm, as represented in ED50 and confirmed
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by p-STAT3 assay (Figures 5D,E). Specifically, whereas the
ARCHA mutation significantly affected Nm biological activity
by >500 fold, this only led to a 10-fold loss of function in
STm. Conversely, the AACHR and RACHR substitutions that
did not dramatically modify STm activity led to a similar loss of
function in the STm as the ARCHA mutation. Collectively, the
inactivation of one monomer of STm led to a weaker binding
to IL-10R; moreover, the impact on the biological activity of
amino acid substitution at the RRCHR region was higher in Nm
than STm.
Stabilized Mouse IL-10 Dimer Is
Biologically Active in vivo
While the above data demonstrated the improved biological
activity and stability of STm in vitro, it was essential also to
examine the efficacy of STm in vivo. The efficacy of STm
compared to Nm under physiological conditions was first
examined utilizing a local inflammatory reaction in the skin
of mice. The skin consists of a multilayer structure of the
epidermis, as well as the bluish coloration of the basophilic
epithelial cytoplasm (Figures 6A,B). Subcutaneous injection
of LPS causes a dose-dependent inflammatory infiltration of
all layers of the skin (37). Our previous data showed that
this reaction is much more severe in IL-10−/− mice, with
considerable necrosis of epidermis, dermis, and panniculus
carnosus (37). This result indicates the importance of IL-
10 in modulating the inflammatory response to LPS in the
skin, validating the model to assess the in vivo effectiveness
of STm in controlling inflammation. Different concentrations
of the IL-10 proteins were injected subcutaneously (under
the panniculus carnosus) together with LPS (10 µg) into IL-
10−/− mice. On 3 consecutive days, an injection was made in
the same place in the flank. On the 5th day, the mice were
sacrificed, and the tissue removed from the injection site and
examined histologically. This experiment showed that injections
of LPS without IL-10 resulted in a massive inflammatory local
reaction with massive recruitment of numerous macrophages
and neutrophils (Figures 6C,D). Moreover, all layers of the
skin in the center of the lesion became necrotic compared
to healthy skin. The enlargement view (Figure 6D) showed
a necrotic hair follicle and necrotic interfollicular epidermis
with condensed nuclei and reddish acidophilic cytoplasm as
opposed to the basophilic cytoplasm of healthy keratinocytes.
Coadministration of STm along with LPS (Figure 6E) suppressed
the inflammatory response in a dose-dependent fashion. In
Figure 6F, we summarize the biological activities of STm and
Nm in protecting LPS induced inflammation. Both STm and
Nm were protective at 2 and 0.2 µg. STm appeared to be more
effective than Nm at 0.02 µg, where the biological activity of
Nm was waning. At 0.002 µg, both Nm and STm had no
protective effect against skin inflammation (Figure 6F). This
experiment demonstrated the biological effect of STm in vivo
but did not allow a quantitative comparison between Nm
and STm.
The activity of STm was also tested using an in vivo model
of LPS-induced systemic inflammation. First, the time course
of TNF concentration in serum after retro-orbital (i.v.) LPS
injection was determined in establishment experiments. A high
serum concentration of TNF ∼3.2 ng/mL was measurable 1.5 h
after the administration of LPS (25 µg i.v.). This value was
reduced by about 75% after 3 h and had returned close to
baseline levels 6 h after LPS injection. Injections of PBS or Nm
and STm (2 µg each) alone did not result in the measurable
release of TNF, which could exclude contamination of these
reagents with pyrogens (Figure 7A). In the next experiment,
different amounts of STm i.v. were injected 30min before LPS
(25 µg i.v.). Here, the STm proved to be highly effective, in
a dose-dependent manner, in the suppression of TNF release.
The administration of 2 µg Nm and STm reduced serum
TNF concentration by ∼70% relative to the control mice
receiving only LPS. Both at either 2 or 20 µg, Nm and
STm were equally effective at suppressing TNF production
(Figure 7B). Apparently, in this assay, the maximum level of
TNF suppression was reached at 2 µg IL-10, as the injection
of 20mg IL-10 failed to suppress TNF production further.
Experiments with titrations of Nm- and STm, however, showed
large fluctuations in TNF serum concentration and therefore
did not allow a quantitative comparison of the effects of Nm-
and STm (data not shown). Therefore, we investigated the
ability of Nm and STm IL-10 to inhibit the production of IL-
6, which is another cytokine integral within the acute phase
inflammatory immune response. The serum concentration of
IL-6 was determined 3 h after injection by ELISA. It was
found that over a wide dose range, the STm reduced IL-6
release more effectively than Nm. By non-linear regression, Nm
suppressed the IL-6 response with an ED50 value of 274.8 ng/mL,
whereas STm suppressed IL-6 production with an ED50 of
112 ng/mL. Thus, STm was ∼2.5-fold (Figure 7C) more potent
than Nm. Altogether, the stable form of IL-10 is biologically
active in vivo, which controls both the local and systemic
inflammatory responses.
The Biological Activity and Stability of
Stabilized Human IL-10 Dimer in vitro
Our results demonstrated that STmmolecules could be generated
with potent regulatory activity. Consequently, given the aim of
developing an IL-10 based treatment for human disease, we
investigated whether it was also possible to create a biologically
active and stable version of human IL-10. We first generated
and produced a stable human IL-10 using different lengths of
the flexible linker (Figure S2A). Our data showed that both Nh
and STh, with different linker lengths, are biologically active
in vitro by suppressing LPS-induced luciferase expression in
BMDMs from the h.TNF.LucBAC reporter mice (Figure 8A).
STh had a 2.5-fold higher biological activity thanNh, asmeasured
by p-STAT3 activation (Figure 8B), which was confirmed by
conventional TNF ELISA assay (Figure S2B). Like the mouse
IL-10, the effect of human IL-10 on luciferase suppression
was blocked by using mouse anti-IL-10R1 in a dose-dependent
manner. Interestingly, our data demonstrate that increased
amounts of anti-IL-10R1 antibody were required to block the
effect of STh in suppressing luciferase production than to block
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FIGURE 5 | The effect of amino acid substitution at the RRCHR region of mouse IL-10 on biological activities. (A) The secondary structure of IL-10 mutants by CD
spectroscopy adopted from unpublished data (36). (B) The ED50 of natural IL-10 was calculated as flow: NmRRCHR (un-mutant) (black line) (0.1 ng/mL), NmRACHR
(green line) (0.28 ng/mL), NmAACHR (blue line) (0.96 ng/mL), and NmARCHA (red line) (59.28 ng/mL). (C) The activation of cellular signaling (p-STAT3) determines by
western blot after lysate from spleen cells of the C57BL/6 mouse treated Nm mutants and un-mutant (control) in dose-response and using the total STAT3 as an
internal control. (D) The ED50 of stable IL-10 was calculated as flow: STmRRCHR (un-mutant) (black line) (0.36 ng/mL), STmRACHR (green line) (1.6 ng/mL), STmAACHR
(blue line) (2.55 ng/mL), and STARCHA (red line) (3.02 ng/mL). (E) The activation p-STAT3 determines by western blot from spleen cells lysate of the C57BL/6 mouse
treated STm mutants and un-mutant (control) in dose-response and using the total STAT3 as an internal control. The data represented as AUC (Area Under the Curve).
All data are representative of two independent experiments, with triplicate cultures per experiment (N = 2, n = 3), and bars represent standard error of the mean.
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FIGURE 6 | Suppression of LPS-induced dermal inflammation by Nm and STm. (A) Overview of healthy skin. Mouse skin consists of a 1–2-layer epidermis (Ep),
which forms the hair follicles (Hf) and sebaceous glands (Td) by invagination in the dermis (De). The dermis consists of collagenous connective tissue. This is followed
by the muscle layer of the Panniculus carnosus (Pc), the fatty tissue (Fg), and the trunk muscles (Rm). (B) Enlargement of healthy skin. The epithelium shows bluish
cytoplasm and loose chromatin, as well as two intact hair follicles. (C) Overview of necrotic skin. In magnification, a large number of neutrophils is recognizable. (D)
Enlargement of necrotic skin. The epithelial cells show reddish cytoplasm and condensed chromatin. The hair follicle is dead. (E) Overview skin section treated STm (2
µg) STm, which LPS was co-injected. (F) A table summarizing the effect of IL-10 (Nm/STm) at different concentrations on LPS-treated (10 µg) skin.
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FIGURE 7 | Detection of the in vivo activity of the STm by suppression of LPS-induced cytokine release. (A,B) 100 µl PBS containing 25 µg LPS i.v. Injected in
C57BL/6 mice (8–12 weeks). At the indicated time points, blood was taken retro-orbitally, and ELISA determined the TNF-a serum concentration, *n.d.: not
detectable. (A) To establish, LPS, PBS, Nm, or STm (2 µg protein each) were injected one at a time. (B) 30min before LPS administration, the indicated amounts of
Nm or STm were i.v. Injected. (C) IL-10 -/- mice were given 10 µg LPS together with increasing concentrations of Nm or STm i.v. Injected. After 3 h, blood was drawn,
and the IL 6 serum concentration determined by ELISA.
the effect of Nh (Figure 8C). This data may indicate the binding
of STh to mouse IL-10R is of higher affinity compared to
the Nh.
In terms of stability, both STh and Nh were incubated during
a time course at 37◦C, which showed no significant difference
in luciferase inhibition (p > 0.5, ANOVA) (Figure 8D), which
indicates the both Nh and STh are biologically active at
physiological temperature. However, Nh gradually lost biological
activity after 5min of heat treatment at 55◦C, whereas STh
maintained biological activity as measured by luciferase assay
(Figure 8E) and TNF-ELISA (Figure S1B). In a dose-response
experiment, we also observed that Nh became less potent
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FIGURE 8 | Generation and characterization of the stable version of human IL-10. (A) The effect of STh (with different linkers length) and Nh on LPS-induce luciferase
activity on BMDMs of transgenic mouse: the ED50 of Nh(black line) is 0.87 ng/mL and the ED50 of STm proteins: STh7 (green) STh9 (blue), and STh13 (red) is
calculated as 0.82, 1, and 1.2 ng/mL, respectively. (B) Splenocyte lysates of the C57BL/6 mouse either unstimulated (∅) or stimulated with IL-10 (Natural type or
Stable) in a dose-dependent manner. (C) The effect mouse antiIL-10 receptor antibody (clone 1B1.3a) on blocking the suppression induced by Nh and STh
(10 ng/mL) in a dose-dependent fashion. Furthermore, a significant difference is also calculated to compare Nm with STm after antiIL-10Ra treatment; ANOVA. (D)
Luciferase activity represented as AUC from LPS-induced BMDMs co-treated with either Nh (black line) and STh (blue line) at 10 ng/mL after incubated at 37◦C in the
time course. (E) Both Nh and STh were incubated at 55◦C in time course, and the luciferase activity was calculated after LPS-stimulated and co-treated with either
Nm (black line) and STm (blue line) at 10 ng/mL on BMDMs. (F,G) LPS-induced Luciferase activity when co-stimulated with either heat-treated at 55◦C for 10min
(10min) or untreated (0min) of Nh and STh. The ED50 is calculated as follow: (F) Nh heat-treated for (3.74 ng/mL) or untreated (0.17 ng/mL); (G) STh heat-treated for
(0.10 ng/mL) or untreated (0.12 ng/mL). (H) Both Nh and STh at 100 ng/mL were pre-incubated with different pH buffers at 4◦C for 24 h flowed by buffer exchange
columns. BMDMs of the transgenic mouse then stimulated with LPS (10 ng/mL) and pH-treated IL-10 (Nh and STh) at 10 ng/mL. The percentage of luciferase
activities is relative to the maximum LPS induction of luciferase. The significant difference compared between pH treatments with neutral pH (pH7) of Nh and STh on
LPS-stimulated cells; ***p < 0.001, **p < 0.005; ANOVA. All the data above are representative of three independent experiments, with triplicate cultures per
experiment (N = 3, n = 3), and bars represent standard error of the mean.
after heat treatment (55◦C for 10min) (Figure 8F); however,
STh maintained suppressive activity (Figure 8G). The pH-
dependent stability study showed that STh behave similarly
to Nh, but, the STh was more resistant in pH5 and pH2
(Figure 8H). Overall, these data show that the STh is a
biologically active protein in vitro with higher stability compared
to Nh.
Overall, we generate a stable IL-10 dimer by linking two IL-10
monomers in a head to tail fashion by a flexible linker (Figure 9).
We demonstrate that our novel stable IL-10 dimer is more stable
in different stress conditions compared to non-covalently linked
IL-10 (i.e., natural IL-10).We assume the stable IL-10 dimer folds
as natural IL-10. The IL-10 3D domain-swapped dimerization of
IL-10 is essential to form the receptor binding site of the cytokine
(13). Ourmutational experiment has indirectly proved that stable
IL-10 dimer binds and acts by the IL-10 receptor.
DISCUSSION
Soon after the cytokine IL-10 was cloned, we generated a
mouse mutant deficient for IL-10 and could show that these
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FIGURE 9 | Scheme representing the proposed biological activity and stability of stable IL-10 dimer. Both natural and stable IL-10 are biologically active in vitro and in
vivo. We predict that our stable IL-10 is folded like the natural IL-10 in a domain-swapping fashion. Our mutant IL-10 model demonstrates the importance of
dimerization to elicit the maximum inhibitory response. We showed that stable IL-10 is more active after treatment with different physiological stress conditions such
as high-temperature and pH compared to natural IL-10.
mice developed inflammatory bowel disease that depended on
the microflora (21). Based on these findings and subsequent
preclinical trials, it was shown that while recombinant IL-10
was safe and well-tolerated in healthy individuals (38), it had
limited efficacy in treating inflammatory diseases (39). In this
report, we reach an important milestone for the generation of
a recombinant IL-10 with more stable biochemical properties.
Syto et al. studied the structural and biological stability of
non-covalently linked IL-10 dimer under different conditions.
It was observed that incubation of human IL-10 dimer for
1 h at 37 and 55◦C resulted in the formation of 2 and 22%
monomers, respectively (9). By the covalent fusion of two IL-
10 monomers, we generated a more stable and most likely
also more biologically active form of IL-10 both for mouse
and human (Figures 2, 8). The previous study demonstrates
that the covalent fusion of dimeric HIV-1 proteases has been
shown to improve protein stability compared to natural dimer
(30). However, the mechanism of this stability enhancement
is not clear. Our possible explanation is that linking the C-
terminus of one IL-10 monomer to the N-terminus of the
second monomer may increase the stability of the IL-10 3D
domain-swapped dimer. The IL-10 3D domain-swapped dimer
defined as the exchange of the helices E and F (from the first
monomer) into the hydrophobic cleft (helices A-D) of the other
monomer, which may not be profoundly affected by the different
conditions of stress in stable IL-10 compared to the natural IL-
10. This study did not define the potential of refolding stable
IL-10 to the known active state after different stress-inducing
conditions were applied. We could demonstrate that the new
IL-10 dimer binds and acts via the IL-10 receptor, shown that
it does not act on IL10R1 deficient lymphocytes (Figure 2A),
by blocking the biological activity using anti-IL-10 receptor
antibodies (Figure 2F) and by introducing point mutations in
the covalent linked IL-10 dimer suggested to be involved in IL-
10 and IL-10 receptor interaction (Figure 4). A previous study
suggested that IL-10 dimer formation is vital to generate the
receptor-binding domain that activates IL-10R signaling via side
to side interaction (13). Therefore, it is believed that the correct
dimer formation (i.e., 3D domain swapping) in IL-10 is essential
to create a receptor-binding domain (13). This hypothesis has
been confirmed by generating a stable monomeric form as a
model to bind to IL-10R in 1:1 interaction (40). The next step
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along this line is to generate crystal structures for the new IL-
10 proteins and to compare these to the known IL-10 structure
(33). Our recombinant stable dimeric IL-10 can now be used as a
building block for the development of IL-10 based therapeutic.
One of the new features of our stable IL-10 is that we can
now prepare asymmetric IL-10 variants as we have control
over the complete IL-10 dimer. We can modify each IL-10
molecule in the dimer independently and get 100% variants with
a defined order of each of the monomers. This allows in the
future more insights into the functional analysis of IL-10 with
its receptor and fine-tuning of the biological activity of the stable
IL-10 protein.
Using the conditional gene targeting approach, we generated
mouse mutants with selective gene inactivation of the IL-
10 (41) and the IL-10R (23). Using these mutants in many
different settings, we have clear evidence that IL-10 is a local
acting cytokine, and there is an apparent cell-type specificity
at both at the level of the IL-10 producing and at the
level of the IL-10 responding cell. For example, in the T-
cell specific IL-10 deficient mouse mutant (41), only T cell-
specific responses are dysregulated, while innate responses are
unaffected. In contrast, in a macrophage-specific IL-10 receptor-
deficient mouse mutant, the T cell responses are unaffected
while innate responses are disturbed similarly to IL-10−/− mice.
These experiments suggest that the next step toward an IL-
10 based therapeutic recombinant protein will be to make an
IL-10 protein that can mimic the local acting property of IL-
10.This might be achieved by joining our recombinant stable
IL-10 to other protein domains that can bind to local regions
and/or to specific cell types. Of note, we have generated a
fusion protein of IL-10 with an antibody and could see that
both the IL-10 activity and the antibody binding property
is present in the fusion protein (work in progress). One of
the challenging steps in the engineering is to use a form
of IL-10 that is less active compared to the natural IL-10
protein in order to allow IL-10 action only when a high local
concentration of IL-10 through the local accumulation of the
IL-10 protein through the antibody part. Examples of such IL-
10 weakening mutations are presented in this report (Figure 4).
We presume that we are maybe even able to generate a local
acting IL-10 inhibitor, in which one of the two dimers is
mutated in a way that the stable IL-10 dimer binds to one
of the IL-10 receptor chains and blocking dimerization of
the receptor.
In conclusion, the effect of IL-10 in clinical trials is limited
due to pleiotropic properties on different cells, and the rapid
dissociation of the homodimer at the site of inflammation. Our
stable IL-10 protein could be a potential building block for
generating a potent and more effective and selective IL-10-based
immunotherapy for treating inflammatory diseases and cancers.
For instance, a stable IL-10 dimer has already been proposed
as a model for generating a target IL-10 immunotherapy
because it has a higher biological activity compared to the
natural IL-10 monomer (42) and the IL-10 dimer proposed
here would allow constructing such cell-type-specific local
acting IL-10.
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